RxDoctor Payments Data

Kristina Roddy, MD

Infectious Disease · Albany, NYNPI 1659415693

Payments from drug & device makers

$9,453in general payments, 2019–2025

Across 438 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$1K
  • Merck$1K
  • AbbVie$938
  • Astellas Pharma US Inc$844
  • Johnson & Johnson$617
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$9,23498%
  • Education$2182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,453 in reported general payments places this provider in the 80th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$53,242
Medicare patients
197
Services billed
532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala77$302,923
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf26$126,501
TriumeqAbacavir/Dolutegravir/Lamivudi21$78,158
DovatoDolutegravir Sodium/Lamivudine22$66,372
DescovyEmtricitabine/Tenofov Alafenam12$26,006
Cefpodoxime Proxetil12$3,405
Daptomycin16$3,015
Amoxicillin93$1,394
CefuroximeCefuroxime Axetil45$1,230
Cefazolin Sodium21$1,199
Doxycycline Hyclate41$978
Fluconazole12$582
ValacyclovirValacyclovir Hcl12$498
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$360
Cefadroxil23$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,424$328,92989 claims
Viiv Healthcare CompanyTriumeq, Dovato$2,486$144,53043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 799 infectious disease providers in New York.

Other infectious disease in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →